Results 21 to 30 of about 10,751 (182)
Frontiers in Oncology, 2021 BackgroundPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopic technique for local chemotherapy. It has been used for treatment of peritoneal metastasis of gastric cancer (PM GC) in combination with systemic therapy.
Linda Feldbrügge +8 more
doaj +1 more source
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. [PDF]
Int J CancerAntiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Hille J +17 more
europepmc +2 more sources
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study. [PDF]
, 2021 Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in
Molero, Alberto +51 more
core +1 more source
Scientific Reports, 2022 Sorafenib, an oral multiple kinase inhibitor, is the standardized treatment for hepatocellular carcinoma (HCC). One strategy to improve HCC therapy is to combine agents that target key signaling pathways.
Amna Mohamed Taha +3 more
doaj +1 more source
BMJ Open, 2020 Objective To investigate the cost-effectiveness of ramucirumab plus erlotinib compared with placebo plus erlotinib in the first-line setting for patients with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) from the Chinese healthcare system ...
Xiaohui Zeng +6 more
doaj +1 more source
Ramucirumab – egy új gyógyszer az onkológiában | Ramucirumab – a new anticancer agent [PDF]
, 2016 Absztrakt A ramucirumab egy humanizált vascularis endothelialis növekedési faktor receptor-2 elleni monoklonális antitest, amely megakadályozza a vascularis endothelialis növekedési faktor-A, -C
András Telekes +3 more
core +1 more source
, 2022 Supplementary Table 1. Overview of targeted therapeutics approved for advanced gastric cancer Supplementary Table 2: Published real-world studies on ramucirumab-containing regimens in AGC Supplementary Table 3.
Kensei Yamaguchi (3626987) +5 more
core +1 more source
Pakistan Journal of Pharmaceutical Sciences, 2020 To carry out a preliminary clinical trial to compare the effectiveness and safety of pemetrexed based chemotherapy regimen in combination of cisplatin versus ramucirumab plus erlotinib in Chinese patients with metastatic non-small-cell lung cancer (NSCLC)
Qin Mei +3 more
doaj +1 more source
BMC Cancer, 2020 Background Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care.
Sadayuki Kawai +11 more
doaj +1 more source
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer [PDF]
, 2018 PURPOSE: Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as ramucirumab.
Conca, Raffaele +20 more
core +1 more source